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Osteosarcoma (OS) is a bone malignancy that affects children and adolescents. It is a highly aggressive
tumor and typically metastasizes to lungs. Despite aggressive chemotherapy and surgical treatments, the
current 5 year survival rate is 60–70%. Clinically relevant models are needed to understand OS
pathobiology, metastatic progression from bones to lungs, and ultimately, to develop more efﬁcacious
treatment strategies and improve survival rates in OS patients with metastasis. The main goal of this
study was to develop and characterize an in vivo OS model that will allow non-invasive tracking of tumor
progression in real time, and aid in studying OS pathobiology, and screening of potential therapeutic
agents against OS. In this study, we have used a multi-modality approach using bioluminescent imaging,
electron microscopy, micro-computed tomography, and histopathology to develop and characterize a
preclinical Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model, using 143B human OS cell
line. The results of this study clearly demonstrate that the BOOMmodel represents the clinical disease as
evidenced by a spectrum of changes associated with tumor establishment, progression and metastasis,
and detection of known OS biomarkers in the primary and metastatic tumor tissue. Key novel ﬁndings of
this study include: (a) multimodality approach for extensive characterization of the BOOM model using
143B human OS cell line; (b) evidence of renal metastasis in OS orthotopic model using 143B cells;
(c) evidence of Runx2 expression in the metastatic lung tissue; and (d) evidence of the presence of
extracellular membrane vesicles and myoﬁbroblasts in the BOOM model.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma (OS) is the most common malignancy of bone,
mainly affecting children, adolescents and young adults. According
to the American Cancer Society, 750–900 new cases of OS are
diagnosed annually [1]. It usually occurs near rapidly growing areas
of long bones, such as distal femur, proximal tibia and humerus near
metaphyseal growth plates [2]. Osteosarcoma is a highly aggressive
tumor and typically metastasizes to lungs. The majority of OS. This is an open access article un
and Oncology, Department
enter, Kansas City, KS 66160,
lla).patients at presentation have pulmonary micrometastases that are
mostly undetectable by current diagnostic tools [3,4]. Despite
aggressive chemotherapy and surgical treatments, the current 5 year
survival rate is 60–70%. To improve survival rates in patients with
metastasis or relapsed OS, clinically relevant models are needed to
understand OS pathobiology and develop more efﬁcacious treat-
ment strategies. In vitro studies using OS cell lines are greatly limited
owing to biological complexity and tissue heterogeneity of the
tumor. Clinical tissue samples from OS patients are suboptimal in
providing important information on dynamic tumor–stroma inter-
actions as intense chemotherapy often disrupts the cellular compo-
nents of the extracellular matrix network and induces cytotoxic
effects. Obtaining clinical samples from pediatric patients for
research studies is a major limitation. Development and application
of reliable animal models is essential to better understand theder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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screening of potential chemotherapeutic agents. Even though there
are numerous studies reporting OS xenograft and allograft models
using either mouse or human OS cells, [5–7] those models fail to
provide information on the tumor microenvironment (TME). In this
context, orthotopic models are extremely valuable as they faithfully
recapitulate human disease in terms of tumor onset, progression,
and metastasis, [8] and provide important information not only on
tumor biology and responsiveness to chemotherapy, but also on
TME. Genetically engineered models further advance our under-
standing of genetic basis of this aggressive disease [9,10]. The
knowledge gained is potentially signiﬁcant in discovering new
targets to block metastasis in the pre-clinical setting and eventually
design metastasis directed therapies for effective OS management.
In recent years, bioluminescent in vivo imaging system (IVIS) has
emerged as an important technology in cancer biology to track
tumor progression in real time in a non-invasive manner, and in
reducing the number of animals needed in in vivo studies. The
bioluminescent IVIS system is a highly speciﬁc and sensitive
imaging modality, and is based on the detection and quantitation
of signal produced by an enzymatic reaction in which luciferin a
substrate is oxidized by luciferase expressing tumor cells, in the
presence of oxygen and ATP. To the best of our knowledge, there are
very few reports which describe in vivo characterization of ortho-
topic bioluminescent OS models (143B-based) in a comprehensive
manner [11–13]. Since multiple genetic risk factors are involved in
the etiology of OS, it is important to develop and characterize
especially those models that closely represent human disease.
In this paper, we describe the development and characterization of
a bioluminescent OS orthotopic mouse (BOOM) model using human
OS cell line 143B. This cell line has a mutation in p53 and
K-ras genes, and when injected orthotopically in immunocompro-
mised mice, results in a highly aggressive form of OS. Themain goal is
to apply the BOOM model to advance our understanding of OS
pathobiology, and to aid in the preclinical screening of potential
therapeutic agents that effectively inhibit OS metastasis. In conjunc-
tion with bioluminescent imaging, we have employed micro-
computed tomography (mCT) to quantify intra-osseous tumor growth
and changes in the bone microarchitecture, and histopathology to
assess histological changes at the primary and metastatic tumor sites.
Micro-CT is a powerful and sophisticated tool to monitor structural
and morphological changes in bone in 3D. The 3D nature of mCT
allows a detailed assessment of changes occurring in the cortical and
trabecular bone. Establishment of tumor and its subsequent metas-
tasis to distant sites like lungs and kidneys was evaluated by
histochemical staining for the detection of unmineralized osteoid
and for the presence of tumor biomarkers such as Ki-67, Runx2, a-
smooth muscle actin and ezrin by immunohistochemistry. We have
used transmission electron microscopy (TEM) to detect the presence
of extracellular membrane vesicles (EMVs) and myoﬁbroblasts in the
primary tumor tissue. Extracellular membrane vesicles are nano-
sized membrane bound entities which mediate intercellular commu-
nication via horizontal transfer of proteins, mRNA and miRNA [14].
Tumor derived EMVs support tumor cell proliferation, survival,
invasion and metastasis either directly or indirectly by modifying
stromal microenvironment. It is our hypothesis that EMVs derived
from cancer cells mediate transdifferentiation of normal stromal
ﬁbroblasts or mesenchymal stem (MSCs) cells to myoﬁbroblasts.2. Materials and methods
2.1. Cell culture
Human OS cell line 143B was purchased from American Type
Culture Collection (Manasas, Virginia) and maintained in DMEMmedium supplemented with 10% fetal bovine serum, antibiotics
including penicillin and streptomycin, 2 mM glutamine and 1
minimal essential medium in 5% CO2 at 37 1C as previously
described [15]. Cells were grown till sub-conﬂuence in T-75 cell
culture ﬂasks and harvested by 0.05% Trypsin/EDTA dissociation.
Exponentially growing cells were used to generate luciferase
expressing puromycin resistant 143B-luc cells.
2.2. Establishment of lentivirally transduced 143B cells expressing
luciferase reporter gene
We engineered 143B cells to express luciferase (FUW-Luc-
mCherry-puro) using a 3rd generation lentiviral vector (FUW) by
following previously published methods speciﬁed for transduc-
tion techniques [16,17]. Positive 143B-luc cells were selected in
puromycin (Sigma Aldrich, St. Louis, MO, USA), expanded and
assayed for luciferase activity using the Dual-Luciferase Reporter
Assay System (Promega Corp., Madison WI, USA).
2.3. Orthotopic intratibial injections
All animal studies were performed at the Proof of Concept
Laboratory (University of Kansas Cancer Center, Kansas City, KS),
with the approval of the University of Kansas Institutional Animal
Care and Use Committee. One million exponentially growing
143B-luc cells were injected orthotopically into Nu/Nu mice,
according to the procedures previously described by Luu et al.
[18] Brieﬂy, the knee was ﬂexed, and about 1106 exponentially
growing 143B-luc positive cells suspended in 100 ml PBS were
injected in the proximal tibias of both legs, using 27 gauge needle.
Tumor growth was monitored weekly for 5–6 weeks by luciferase
imaging, using the Calipers IVIS system. This time point repre-
sents a reasonable end-point for evaluating osteosarcoma bone
colonization, progression, and metastasis in the BOOM model
using histopathology, immunohistochemistry for detection of
disease speciﬁc biomarkers, electron microscopy for detection
and conﬁrmation of myoﬁbroblasts and extra-cellular membrane
vesicles, and micro-computed tomography for assessing the
impact on bone architecture.
2.4. Bioluminescent imaging
Mice were prepared for imaging following intraperitoneal
injection of luciferin. The mice were anesthetized by exposure
to isoﬂurane gas anesthesia (2.5%) before placing them inside the
imaging chamber. Photographic and bioluminescent images were
acquired and superimposed, while still maintaining the anesthe-
tized mice under isoﬂurane atmosphere. Using the Living image
software, a region of interest (ROI) was manually drawn around
the tumor site, and the radiance output or signal was recorded as
the total ﬂux of the ROI and expressed in photons/seconds for
each animal. For ex-vivo imaging to detect luciferase positive cells
at the metastatic site, lungs and kidneys were resected at
necropsy from luciferin injected animals.
2.5. Detection of mCherry positive 143B cells and tumor-induced
histopathological changes
For evaluating ﬂuorescent mCherry positive 143B cells and
tumor-induced histopathological changes, excised tibias (tumor-
bearing), lungs and kidneys were ﬁxed in 4% paraformaldehyde
(pH 7.4). For detection of mCherry ﬂuorescence, 5 mm sections of
excised tumor tissue were examined microscopically. Slides were
imaged on an Olympus IX71 inverted ﬂuorescent microscope
equipped with a xenon arc lamp and monochromatic CMOS camera.
Images were acquired using SlideBook v4.2 image acquisition
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and immunohistochemistry (IHC), tibias were decalciﬁed in 10%
EDTA (pH 7.5) for 2 weeks prior to sectioning and parafﬁn embed-
ding. Tumor-bearing and control tissue sections were stained with
H&E, for histological evaluation of primary tumors and microme-
tastasis in the lungs and kidneys.
2.6. Detection of unmineralized osteoid (a hallmark of OS) by
Villanueva–Goldner staining
To determine osteoid content in tumor-bearing bones, excised
tibias (either tumor-bearing or non-tumor-bearing) were ﬁxed in
4% paraformaldehyde (pH 7.4) and non-decalciﬁed sections were
embedded in methyl methacrylate (MMA) according to a pre-
viously described method [19]. Serial sections of embedded
samples were stained with Villanueva–Goldner stain for the
detection of unmineralized osteoid [20].
2.7. Immunonohistochemistry (IHC)
Unstained tibial, lung and kidney sections were processed
for immunohistochemical analysis. Primary antibodies to Ki-67Fig. 1. Bioluminescent imaging of intra-tibial growth of 143B-luc cells. Mice were injec
luciferase imaging (A). Within 2 weeks, mice developed spontaneous metastasis to lung
lesions is shown (B). Kinetics of 143B-luc generated tumor in real time is shown in C.
is shown in D.(clone MIB-1) and desmin were purchased from Dakocytomation
(Carpinteria, CA). Primary antibodies to Runx2 and ezrin were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Primary antibody to a-smooth muscle actin (a-SMA Sigma–
Aldrich, MO) was generously provided by Dr. Smirnova, Univer-
sity of Kansas Medical Center. The concentrations of primary
antibodies used were as follows: 1:500 for Ki-67; 1:50 for Runx2
and desmin; and 1:200 for ezrin and a-SMA. Expression of ezrin,
Runx2, desmin, a-SMA and Ki-67 was detected using peroxidase
conjugated secondary antibody and a peroxidase substrate
(3, 5-diaminobenzidine). For Ki-67, tonsils and appendix tissue
sections and for Runx2 IHC, spleen and kidney tissue sections were
used as controls. For ezrin tonsil sections, and for desmin and a-SMC
IHC, smooth muscle tissue sections were used as controls.2.8. Transmission Electron Microscopy (TEM)
For TEM, tumor-bearing bones were ﬁxed in 2.5% glutaralde-
hyde, post ﬁxed in 1% osmium tetraoxide (OsO4), dehydrated,
embedded in epon resin and cut into ultra-thin sections. The
sections were stained with uranyl acetate and lead acetate priorted with 143B-luc cells intra-tibially and tumor growth was monitored weekly by
s (A). A representative image of ex-vivo bioluminescent imaging of lung metastatic
Detection of bioluminescent signal in 3D views (coronal, transaxial and saggital)
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photographed using a JEM 1400 electron microscope (80 kV).
2.9. Micro-computerized tomography (m-CT)
For m-CT micro-computerized tomography of tibias, bones were
ﬁxed in 70% ethanol and scanned with a high-resolution mCT (mCT40;
Scanco Medical, Southeastern, PA) as previously described [19]. Data
were acquired at 55 KeV at 6 mm resolution and three-dimensional
reconstructions of bone samples were generated using the following
parameters: Sigma, 0.8; Support, 1; Threshold, 212 (cortex). Cortical
thickness and tissue mineral density were calculated by integration of
the value on each transverse section of a set of 160 slices chosen in
the midshaft area. Tissue mineral density was derived from the linear
attenuation coefﬁcient of threshold bone through precalibration of
the apparatus for the acquisition voltage chosen.
2.10. Statistical analysis
Statistical analysis was performed using Prism 5 (Graph-Pad
software, La Jolla, CA). All experimental data are presented as
mean7S.E.M. Student’s t-test was used for determining statisti-
cal signiﬁcance between control (non-tumor-bearing) versus
tumor-bearing mice (saline treated) groups. A p value o0.05
was considered statistically signiﬁcant.3. Results
3.1. Non-invasive tracking of tumor growth in real time following
injection of 143B-luc cells in Nu/Nu mice
In this study, we developed an orthotopic OS mouse model
using human OS cell line 143B expressing luciferase (143B-luc).
Quantiﬁcation of luciferase activity in serial dilutions ofTable 1
Tumor burden in the BOOM model as detected by bioluminescent imaging (BLI) and h
Experiment # Tumors detected in the BOOM model
BLI (# of mice with detectable tumors) Histology
Bone
1 7 7/7* (*tail
2 9 9/9
Tumor burden (%) 100% (16/16) 16/16 (10
Fig. 2. Photomicrograph illustration showing the presence of mCherry positive 143B-l
(metastatic site) tissue (B).lentivirally transduced 143B-luc cells revealed that 0.3105 cells
was the threshold number of cells to detect luminescence, in vitro.
For 143B-luc cells, total ﬂux/cell was determined to be 2165 p/s/
cell. Following intra-tibial injection, the 143B-luc cells generated
tumors in the medullary cavities of the injected bones that
subsequently metastasized to lungs within two weeks (Fig. 1A–D),
as detected by bioluminescent imaging (BLI). Using the BLI
approach, tumor burdenwas 100 % in the BOOMmodel in 2 separate
experimental trials (Table 1). Ex-vivo bioluminescence conﬁrmed
the presence of 143B-luc cells in the lungs (Fig. 1B). The kinetics of
tumor progression in real time revealed an increase in signal
intensity i.e. the number of photons/second (Fig. 1C).3.2. Histopathological characterization of tumors derived from
143B-luc cells in the BOOM model
Histological examination revealed the presence of ﬂuorescent
mCherry positive 143B-luc cells in parafﬁn embedded sections of
lungs and bones (Fig. 2). Hematoxylin and eosin stained sections
revealed the presence of intramedullary tumor composed of
highly anaplastic polygonal and spindle shaped OS cells in
primary bone and metastatic lesions of tumor-bearing mice
(Fig. 3A–F). The tumor cells had pleomorphic, and hyperchromatic
nuclei. Actively dividing OS cells in different mitotic stages were
detected in the primary and metastatic tumors of tibial, lung and
kidney sections (Fig. 3A–F). Metastatic tumor emboli were also
observed within small and medium sized angiolymphatic vessels
in kidneys. Areas with geographic necrosis were also detected in
the tumor-bearing tissue. Evidence of osteoid formation was
observed in some tumors (Fig. 3E and F). Histopathologial
evaluation of slides revealed the presence of tumors in tibial,
lung and kidney sections. We detected and conﬁrmed the pre-
sence of tumor foci in 16/16 (100%) tibial, 14/16 (88%) lung, and
3/9 (33.3%) kidney sections, at the end of 2 experimental pilotistology.
(# of slides with detectable tumors)
Lungs Kidneys
-vein injection-1) 7/7** (** tail-vein injections-2) 3/5
7/9 0/4
0%) 14/16 (88%) 3/9 (33%)
uc cells (as indicated by an arrow) in the bone (primary tumor site) (A) and lung
Fig. 3. Hematoxylin and Eosin staining showing primary tumor in the tibia (A and B) and OS metastatic lesions in lungs (C and D) and kidney (E and F). The inset shows the
presence of osteoid (pink color) in the tumor. The reader is recommended to zoom to 200% to view tumor cells in different mitotic stages. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Graphic illustrations showing tumor burden proﬁle in the BOOM model from two rounds of experiments. Bone, lung and kidney sections were examined
histogically for the detection of tumors (A). Number of metastatic lesions per lung or kidney sections were also examined (B).
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from 1–50 (Fig. 4b). Metastatic lesions in kidneys were detectable in
fewer number of slides examined. Average tumor burden proﬁle in
the BOOM model from 2 trials, as evaluated histologically is shown
in Table 1 and Fig. 4. Goldner staining on non-decalciﬁed tibial
sections indicated the presence of more osteoid in the tumor tissue
compared to control, thereby indicating the presence of active
osteoid secreting osteosarcoma cells (Fig. 5). High proliferative
activity of OS lesions was conﬁrmed by the increased number of
Ki-67 positively stained cells, as shown in Fig. 6. Expression of ezrin,
an OS metastasis biomarker (Fig. 7A and B), and Runx2 (Fig. 8A–E), a
differential tumor modulator was detected in all OS cell from
primary and metastatic lesions, by IHC. Light microscopy revealed
the presence of ﬁbroblasts in and around the tumor tissue (Fig. 9A).
Expression of a-SMA and desmin was detected in the primary
tumor tissue of the BOOM model (Fig. 9B and C).3.3. Detection of Extracellular Membrane Vesicles (EMVs)
and myoﬁbroblasts in the tumor tissue of the BOOM model
by Electron Microscopy (EM)
Electron microscopic examination of the primary tumor
tissue from the BOOM model revealed the presence of myoﬁ-
broblasts in and around the tumor tissue, and were identiﬁed
based on their cellular content and distinct morphological
features such as presence of abundant Rough Endoplasmic
Reticulum (RER), peripheral distribution of ﬁlaments, ﬁbronec-
tin ﬁbrils and ﬁbronexus (cell-to-matrix junction) (Fig. 10A).
Extracellular matrix vesicles which were about 50–200 nm
in diameter were detected in the extracellular matrix of tumor,
in the vicinity of the cells from which they are derived
(Fig. 10B). Multivesicular bodies were detected in the tumor
tissue (Fig. 10B2).
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Our m-CT results demonstrate that 143B-luc cells in the BOOM
model produced both osteolytic and osteoblastic lesions in the
tibias of tumor-bearing mice (Fig. 11A). These lesions were absent
in (vehicle injected) control tibia. Micro-CT analyses revealed
changes in the bone architecture due to cortical penetration of
tumor in tumor-bearing tibia vs. control tibia (Fig. 11B). BoneFig. 5. Photomicrograph illustration showing the presence of osteoid (pink color)
in the primary tumor as detected by Goldner staining. The osteoid (as indicated by
an arrow) is deposited by rapidly proliferating osteosarcoma cells. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
Fig. 6. Photomicrograph illustration showing Ki-67 (a proliferation marker) immunosta
Arrows indicate mitotic ﬁgures where Ki-67 is maximal.
Fig. 7. Photomicrograph illustration showing ezrin immunostaining in osteosarcoma t
antibody. Brown staining indicates ezrin expression (also indicated by arrows). (For int
the web version of this article.)parameters such BV/TV was signiﬁcantly decreased (po0.0001)
in the tumor-bearing tibia vs. control, while no signiﬁcant
changes were observed in the cortical thickness and cortical bone
mineral density (Fig. 12). Polar moment of inertia (pMOI) which is
an indicator of bone strength was reduced in tumor-bearing tibia
vs. non-tumor-bearing control, but the difference was not sig-
niﬁcance (p¼0.09, nZ3) (Fig. 12).4. Discussion
In this study, we report the development of a preclinical
Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model
and its characterization by bioluminescent imaging, m-CT and
histopathology, using 143B, an aggressive human OS cell line. We
have used bioluminescent imaging for easy detection of
luciferase-tagged cancer cells in real-time, and histopathological
techniques like light microscopy and IHC for morphological and
histopathological characterization i.e. tumor establishment at the
primary site and progression or metastasis to distant sites
including lungs and kidneys. Finally, the impact of intraosseous
tumor growth on local bone microenvironment and architecture
in the BOOM model was assessed using m-CT, and detection of
osteoid by Goldner’s staining.
To our best knowledge, a multi-modality approach to system-
atically characterize an OS in vivo orthotopic model, using an
aggressive OS cell line has not been previously reported. The
advantage of using multi-modality approach i.e. BLI, histopathol-
ogy, immunohistochemistry, and electron microscopy allowed us
to detect tumor cells and disease progression in real time, detect
OS-speciﬁc biomarkers, and successfully detect the presence of
myoﬁbroblasts and extra-cellular membrane vesicles in the
osteosarcoma tissue.ining in actively dividing osteosarcoma cells in tibia (A), lungs (B) and kidneys (c).
umor tissue in tibia and lungs. Panels A and B are treated with anti-ezrin primary
erpretation of the references to color in this ﬁgure legend, the reader is referred to
Fig. 8. Photomicrograph illustration showing immunlocalization and expression of Runx2 in osteosarcoma tissue microarray, 143B human OS cells and tumor tissue of the BOOM
model. Panels A (10 ), B (40 ), C and D demonstrate positive staining in osteoblastic osteosarcoma core sample of bone cancer tissuemicroarrays, 143B human OS cell line in vitro,
and in the tumor tissue isolated from the BOOM model, respectively. Panel E (40X) shows positive immunostaining for Runx2 in metastatic OS lesions in the lung tissue.
Fig. 9. Photomicrograph illustration showing the presence of myoﬁbroblast like cells in the primary tumor tissue of the BOOM model as identiﬁed by light microscopy
(Panel A) and a-SMA (Panel B), and desmin (Panel C) immunostaining.
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model revealed histological features similar to those of clinical
OS as detected by light microscopy, IHC and Goldner staining.Histological detection of newly formed osteoid in our studies
indicates that the 143B cells in the BOOM model proliferate
rapidly, secreting osteoid, and form osteoblastic lesions similar
Fig. 10. Transmission Electron Micrograph composite showing representative images of myoﬁbroblasts and EMVs in the primary tissue of the BOOM model.
The ultrastructural features that are characteristic of myoﬁbroblasts include presence of RER, peripheral distribution of ﬁlaments, and a prominent ﬁbronexus junction
(Panel A). Panel B shows representative images (B1) of EMVs and multivesicular body (B2) in the tumor tissue of the BOOM model.
Fig. 11. Photomicrograph illustration showing representative 3D reconstructions
of mCT scans of control (non-tumor-bearing) vs. orthograft tumor (tumor-bearing).
Osteoblastic (OBL)/osteolytic (OLL) lesions are indicated by an arrow (Panel A).
The lower panel (B) shows representative 3D mCT–generated sections of tibias
showing increased cortical thickening and destruction of cortical bone in tumor-
bearing mice versus control.to neoplastic OS cells in the clinical disease [21,22]. Bone
involvement of the experimental OS was also conﬁrmed by
m-CT which revealed the presence of both osteoblastic and
osteolytic lesions in tumor-bearing bones.
Human OS cell line 143B is derived from TE85 (ras wild type)
OS cell line. The metastatic ability of 143B cells is due to the
activation of K-ras [18]. The propensity of ras-activated tumor
cells to lungs is known [23] but the underlying mechanisms that
facilitate lung metastasis are not clear. While pulmonary metas-
tasis is a common feature associated with OS, we neither know
the frequency of ras mutations nor its association with pulmonary
metastasis in clinical OS. Metastatic OS in the kidney was
detected in the BOOM model. Renal metastasis is rare in clinical
OS, but there are a few studies which report that renal metastasis
develops subsequent to pulmonary metastasis [24–29]. Renal
metastasis of OS is correlated with aggressive cancer and poor
survival [30] and usually detected after death in about 10–12% OS
autopsies [31,32].To our best knowledge, this is the ﬁrst study
that reports renal metastasis in OS orthotopic model using 143B
cells. It is not clear whether the renal metastasis as observed in
few animals in our study is cell-line speciﬁc or due to immune-
incompetence, and/or the chosen animal.
Ezrin is one of most consistent metastasis biomarker of OS and
its role in metastasis is discussed in a number of investigative
studies [33–35]. Ezrin is a protein that links cytoskeleton proteins
like actin to the cell membrane. It plays an important role in
cell–cell interaction and signal transduction [36]. In pediatric
OS patients, increased ezrin expression is correlated with poor
prognosis [37,38] and down regulation of ezrin expression in
murine OS model resulted in inhibition of pulmonary metastasis
[33]. The expression of ezrin in the tumor tissue of bones and
lungs observed in our study supports the clinical relevance of the
BOOM model.
A key pathophysiological feature of OS is the cumulative defect
in osteoblastic differentiation. Runx2 is a transcription factor
which regulates osteogenic differentiation and bone formation.
The role of Runx2 in OS is a subject of intense debate. While some
studies report that OS cells express lower levels of Runx2 and
suggest that Runx2 insufﬁciency contributes towards osteosarco-
magenesis and progression, [39] others report high incidence of
Runx2 genomic ampliﬁcation, [40] and increased Runx2 expres-
sion (mRNA and protein) in OS biopsy samples [41,42]. Increased
Fig. 12. Graphic illustration comparing cortical bone parameters i.e. cortical fraction (BV/TV) (A), cortical bone mineral density (B), cortical thickness (C), and polar
moment of inertia (pMOI) (D) between control (non-tumor-bearing) and tumor-bearing bone (nZ3).
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vant chemotherapy in OS [41]. Presence of increased expression
of Runx2 in the tumor tissue obtained from the BOOM model
conﬁrmed our observation of increased expression of Runx2 in
the osteoblastic type of OS in the bone cancer tissue microarrays.
The presence of myoﬁbroblasts in OS is not surprising as
previous studies have reported the presence of myoﬁbroblasts
in bone tumors [43–46]. To our best knowledge, this is the ﬁrst
study that reports the presence of myoﬁbroblasts in an in vivo OS
experimental model, as identiﬁed by immunoexpression of
a-SMA and characteristic ultrastructural features by TEM. Myoﬁ-
broblasts of the reactive tumor stroma mediate ECM remodeling
mainly by active synthesis of extracellular matrix (ECM) compo-
nents like collagen type I, III, ﬁbronectin, and enzymes like MMPs,
urokinase plasminogen activator and ﬁbronectin activation pro-
tein [47–50]. Expression of a-SMA in OS cells as seen in this study
and others suggest that (a) highly aggressive OS cells may tend to
become de-differentiated and pleomorphic [51], and (b) tumor
cells may fuse with stromal cells such as myoﬁbroblasts from
tumor microenvironment [52]. Previous studies suggest that
expression of a-SMA in OS tissue may be of prognostic signiﬁ-
cance [51–53]. Previous studies report that the expression of
desmin in OS is highly variable (absent to minimal). This could be
attributed to heterogeneity of tumor stroma [54]. Evidence of
strongly positive staining for desmin expression in our OS tissue
could be associated with K-ras mutational background of 143B
cells as previous studies with soft tissue sarcomas have reported
that expression of Kras in satellite cells induced expression of
myogenic proteins such as Myo D and desmin [55].
The tumor microenvironment is enriched with EMVs that are
derived not only by proliferating tumor cells, but also frominﬁltrating macrophages and neutrophils, and support tumor cell
survival, growth, invasion and metastasis. Tumor derived EMVs
also have the potential to modulate surrounding stromal cells,
and facilitate rapid phenotype adjustments for maintaining cel-
lular homeostasis during physiological and pathological states.
In particular, a recent study has demonstrated that exosomes
or EMVs derived from mesothelioma cancer cells can
stimulate differentiation of ﬁbroblasts to a-smooth muscle actin
expressing myoﬁbroblasts [56]. Acquisition of myoﬁbroblast
phenotype in the stromal microenvironment is associated with
increased tumor growth, angiogenesis and metastasis [56,57]. In
our study, we report the presence of both EMVs and myoﬁbro-
blasts in OS tissue, isolated from the primary tumors of the
BOOM model.
A preclinical BOOM model like the one described in this paper
and others [11,12,58] will continue to shed light on OS pathobiology
and tumor microenvironment in primary and metastatic sites. These
models are also invaluable in conducting chemopreventive, che-
motherapeutic and genetic (gene silencing or RNA interference or
gene therapy) studies especially when clinical trials are challenging
because of limited number of samples and the patient category
(pediatric). Our goal is to expand the use of the preclinical BOOM
model and obtain mechanistic information underlying tumorigen-
esis; matrix remodeling, dynamic cross-talk between tumor–stroma;
and metastasis, and screen potential antineoplastic or tumor mod-
ulating agents. Multi-modality application of the preclinical BOOM
model will help to identify new therapeutically relevant targets for
drug development against OS. We anticipate this strategy will
provide a powerful ﬁrst step before further evaluation using natu-
rally occurring in canine OS models (comparative oncology
approach) and then testing in pediatric patients.
R. Garimella et al. / Journal of Bone Oncology 2 (2013) 11–2120Our model has provided a powerful tool for following the
progression of cancer cells in real time. Also, for future studies the
BOOM model provides a platform for collecting information on
threshold-dose of luciferase-tagged OS cell lines to generate
tumors orthotopically, cellular, molecular, histological and m-CT
changes dynamically. One of the limitations of the BOOMmodel is
that it does not allow a ‘‘complete’’ evaluation of host immune
responses to OS. The lymphocyte mediated immune response
especially the T-cell response is lost in the immunocompromised
mouse model [59]. Despite the above discussed limitations, there
are clear scientiﬁc beneﬁts that can be derived from the BOOM
model. For example, as stated previously, the frequency of ras
mutations in clinical OS is unknown, but successful metastasis of
143B cells to lungs and kidneys from tibia i.e. the primary site
demonstrates the reliability of this model to investigate the
mechanism(s) underlying tumor progression and metastasis. In
conclusion, we have successfully developed and characterized a
bioluminescent orthotopic model that can be used to study OS
pathobiology, and to evaluate potential therapeutic agents. Key
novel ﬁndings of this study include: (a) multimodality approach
for extensive characterization of the BOOM model using 143B
human OS cell line; (b) evidence of in vivo Ki-67 staining of 143B
cells; (c) evidence of renal metastasis in OS orthotopic model
using 143B cells, (d) evidence of Runx2 expression in the meta-
static lung tissue, (e) evidence of osteoblastic and osteolytic
lesions with destruction of cortical bone due to increasing tumor
burden; and (f) evidence of the presence of extracellular mem-
brane vesicles and myoﬁbroblasts in the tumor tissue from the
BOOM model, suggesting a possible role of tumor-stroma inter-
cellular communication in osteosarcoma progression.Acknowledgment
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